Follow-The-Filings

Security · featured owners

DNLI Denali Therapeutics Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 3.6%
  • $19M
  • 1 add 2 exits

DNLI (Denali Therapeutics Inc.) is held in 1 featured 13F book as of 2026 Q2. Nathan Fischel - Dafna Capital Management is the largest tracked holder by portfolio weight (3.6%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 3.6% (Nathan Fischel - Dafna Capital Management) · not free-float ownership

  1. Nathan Fischel add 3.6%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Nathan Fischel - Dafna Capital Management 2026 Q2 3.6% Add +132.0% 739,014 $19M history
Palo Alto Investors exited 2026 Q2 last 2026 Q1 0.69% Exit −0.69% 234,582 $5M history
Polen Capital Management exited 2026 Q2 last 2026 Q1 0.01% Exit −0.01% 65,301 $1M history

1 current · 2 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 21 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.01,9.01 Filing Doc
8-K 1.01,7.01,9.01 Filing Doc
8-K 5.07,9.01 Filing Doc
8-K 7.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
DEFA14A DEFA14A ADDITIONAL MATERIALS Filing Doc
8-K 1.02,9.01 Filing Doc
8-K 2.03,7.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 7.01,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,9.01 Filing Doc
8-K 7.01,8.01,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 10 rows shown

Filed Form Detail Links
4 Period Sep 4, 2026 Filing Doc
4 Period Sep 2, 2026 Filing Doc
4 Period Sep 1, 2026 Filing Doc
4 Period Aug 12, 2026 Filing Doc
4 Period Aug 11, 2026 Filing Doc
4 Period Jun 3, 2026 · 8 forms Filing Doc
4 Period Jan 6, 2026 · 2 forms Filing Doc
4 Period Jan 3, 2026 · 2 forms Filing Doc
4 Period Dec 11, 2025 Filing Doc
4 Period Nov 4, 2025 Filing Doc

Updated 3 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $330.53M $0M $0M
Net income -$145.22M -$422.77M -$512.54M
Net margin * -43.9% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $1.06B $0.864B $0.901B
Total non-current assets * $89.78M $509.74M $244.2M
Total assets $1.15B $1.37B $1.14B
Total current liabilities $77.98M $102.21M $98.35M
Total non-current liabilities * $44.98M $42.29M $32.74M
Total equity $1.03B $1.23B $1.01B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$357.99M -$347.69M -$412.6M
Cash from investing $249.31M -$88.76M $255.28M
Cash from financing $17.82M $484.3M $189.22M
Net change in cash -$90.86M $47.85M $31.9M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders